Using Social Media to Facilitate Communication About Women’s Testing: Tool Validation Study by Tara Coffin, Deborah Bowen, Karen Lu, Elizabeth M Swisher, Nadine Rayes, Barbara Norquist, Stephanie V Blank, Douglas A Levine, Jamie Nadine Bakkum-Gamez, Gini F Fleming, Olufunmilayo I Olopade, Iris Romero, Alan D'Andrea, Denise R Nebgen, Christine Peterson, Mark F Munsell, Kathleen Gavin, Jamie Crase, Deborah Polinsky, Rebecca Lechner

“…ConclusionsFacebook is a useful way of enhancing clinical trial recruitment of women aged ≥30 years who have a potentially increased risk for ovarian cancer by promoting news stories over social media, collaborating with patient advocacy groups, and running paid and unpaid campaigns. …”
Get full text

Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway by Andy McKay, Carlos Pantoja, Richard Hall, Sarah Matthews, Phil Spalding, Rajarshi Banerjee

“…Patients and patient advocacy groups were involved in the design and conduct of the study, and analysis of the interview transcripts. …”
Get full text

Establishing Patient-Centered Outcomes for MCT8 Deficiency: Stakeholder Engagement and Systematic Literature Review by Wilpert NM, Tonduti D, Vaia Y, Krude H, Sarret C, Schuelke M

“…However, the EMA and FDA strongly encourage researchers to involve patients and their advocacy groups in the design of clinical trials. This should strengthen the patients’ perspective and identify clinical endpoints that are clinically relevant to their daily life.Methods: We involved patient families to define patient-relevant outcomes for MCT8 deficiency. …”
Get full text

Gene therapy for selected neuromuscular and trinucleotide repeat disorders – An insight to subsume South Asia for multicenter clinical trials by Nalaka Wijekoon, Lakmal Gonawala, Pyara Ratnayake, Darshana Sirisena, Harsha Gunasekara, Athula Dissanayake, Sunethra Senanayake, Ajantha Keshavaraj, Yetrib Hathout, Harry W.M. Steinbusch, Chandra Mohan, Ashwin Dalal, Eric Hoffman, K.Ranil D de Silva

“…By fostering collaboration between researchers, clinicians, patient advocacy groups, government and industry in gene therapy initiatives for the inherited-diseases community in the developing world would link the Global North and Global South and breathe life into the motto “Together we can make a difference”.…”
Get full text

Material Sustainability and Value Creation: Adapting SASB Standards in the Iranian Context by Samira Joudi, Gholamreza Mansourfar, Saeid Homayoun, Zabihollah Rezaee

“…In recent decades, a new form of investment, known as "sustainability investment," has attracted interest from companies, institutional investors, and social advocacy groups. This research aims to investigate the impact of investment in material sustainability activities on the value creation of companies in the oil and gas, metals, mines, and coal mining industries listed on the Tehran Stock Exchange from 2016 to 2021. …”
Get full text

The Challenges of Preventive Screenings by Stephanie Holmquist

“…Preventive Services Task Force (U.S.P.S.T.F) recommended against routine screening for women under 50 and only bi-annual screens for older women 3 Pushback from physician and breast cancer advocacy groups to the U.S.P.S.T.F. recommendations is echoed by immediate challenges to the new Canadian report. 3, 4 On the prostate cancer front, screening for prevention may soon take a step forward.  …”
Get full text

Cost of disorders of the brain in Slovenia in 2010 by Jurij Bon, Blaž Koritnik, Mara Bresjanac, Grega Repovš, Peter Pregelj, Bogdan Dobnik, Zvezdan Pirtošek

“…The reported results should be considered by all stakeholders, including policy makers, industry and patient advocacy groups, to reconsider the current science, research and public health agenda and shape a coordinated national action-plan to address the imminent challenges posed by disorders of the brain.…”
Get full text

Manejo de la fibrilación auricular no valvular desde la perspectiva del paciente en España by Almudena Castro, Luciano Arochena, Maite San Saturnino, Carmen Aleix, Alexandra Solé, Natalia Malé, Clara Gabás-Rivera, Luis Lizán

“…Methods: Observational study conducted with Spanish patient advocacy groups, based on a specific questionnaire requesting: 1) sociodemographic/clinical variables; 2) information received on NVAF and current treatment; 3) anticoagulant treatment preferences; 4) treatment burden and access barriers. …”
Get full text

Personalizing medicine: a systems biology perspective by Deisboeck, Thomas S.

“…Although pressure from patients, advocacy groups and funding agencies is mounting, the conventional populationbased approach for therapeutic developments in clinics still relies on passing a series of randomized controlled trials that depend on enrollment of many patients in search for favorable yet averaged outcome patterns that statistically document safety and efficacy. …”
Get full text

Electronic cigarettes for smoking cessation by Hartmann-Boyce, J, McRobbie, H, Bullen, C, Begh, R, Stead, L, Hajek, P

“…Smokers report using ECs to reduce risks of smoking, but some healthcare organizations, tobacco control advocacy groups and policy makers have been reluctant to encourage smokers to switch to ECs, citing lack of evidence of efficacy and safety. …”

The Women@Heart NS Pilot Project: Rationale and Design of a Community-Based Peer Support Program for Women Living With Heart Disease in Nova Scotia by Zoya Gomes, BSc, MSc, Nadine Elias, BSc (Kin), Kerri A. Mullen, BSc, MSc, PhD, Nicole Nickerson, Wanda Firth, PDt, Cynthia Kendell, BSc (Kin), MScHK, PhD, Laura Jimenez, BSc, Jennifer Jones, MD, FRCPC, Sharon L. Mulvagh, MD, FRCPC, FASE, FACC, FAHA

“…The program aims to empower women with coping strategies, provide a supportive learning environment, and establish volunteer advocacy groups. The primary objective of this study is to evaluate the implementation feasibility of the W@H program for women living in Nova Scotia. …”
Get full text

Electronic cigarettes for smoking cessation by Hartmann-Boyce, J, Lindson, N, Butler, AR, McRobbie, H, Bullen, C, Begh, R, Theodoulou, A, Notley, C, Rigotti, NA, Turner, T, Fanshawe, TR, Hajek, P

“…Some people who smoke use ECs to stop or reduce smoking, although some organizations, advocacy groups and policymakers have discouraged this, citing lack of evidence of efficacy and safety. …”

Electronic cigarettes for smoking cessation by Hartmann-Boyce, J, McRobbie, H, Lindson, N, Bullen, C, Begh, R, Theodoulou, A, Notley, C, Rigotti, NA, Turner, T, Butler, AR, Hajek, P

“…People who smoke report using ECs to stop or reduce smoking, but some organisations, advocacy groups and policymakers have discouraged this, citing lack of evidence of efficacy and safety. …”

Electronic cigarettes for smoking cessation by Hartmann-Boyce, J, McRobbie, H, Lindson, N, Bullen, C, Begh, R, Theodoulou, A, Notley, C, Rigotti, NA, Turner, T, Butler, AR, Fanshawe, TR, Hajek, P

“…Some people who smoke use ECs to stop or reduce smoking, but some organizations, advocacy groups and policymakers have discouraged this, citing lack of evidence of efficacy and safety. …”

Electronic cigarettes for smoking cessation by Hartmann-Boyce, J, McRobbie, H, Butler, AR, Lindson, N, Bullen, C, Begh, R, Theodoulou, A, Notley, C, Rigotti, NA, Turner, T, Fanshawe, TR, Hajek, P

“…Some people who smoke use ECs to stop or reduce smoking, but some organizations, advocacy groups and policymakers have discouraged this, citing lack of evidence of efficacy and safety. …”

The Study Area by Donya Ahmadi, Tuna Tasan-Kok

“…(CIC, 1998) The recommendations within the document, particularly those in relation to the family class, sponsorship and spousal immigration fuelled many public debates and active criticism –especially by women’s organisations and female advocacy groups. Furthermore, the structural changes and welfare cuts initiated by the progressive conservatives in mid-1990s continued when the new Harper government implemented reforms in 2008. …”
Get full text

Examining Clinical Ethics by Matt Dias

“…Because BIID is an “underground” condition, there are no advocacy groups pursuing legislation due to the condition’s rareness and since “the idea of wanting to be disabled is inherently less acceptable to people.” …”
Get full text